Cerity Partners LLC Boosts Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Cerity Partners LLC raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,463 shares of the company’s stock after purchasing an additional 189 shares during the quarter. Cerity Partners LLC’s holdings in Medpace were worth $755,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. CWM LLC increased its stake in shares of Medpace by 554.3% during the 3rd quarter. CWM LLC now owns 1,518 shares of the company’s stock worth $368,000 after purchasing an additional 1,286 shares during the last quarter. IFP Advisors Inc increased its position in Medpace by 144.3% in the third quarter. IFP Advisors Inc now owns 171 shares of the company’s stock worth $41,000 after buying an additional 101 shares during the last quarter. SG Americas Securities LLC increased its position in Medpace by 353.2% in the third quarter. SG Americas Securities LLC now owns 2,515 shares of the company’s stock worth $609,000 after buying an additional 1,960 shares during the last quarter. Impact Partnership Wealth LLC bought a new stake in shares of Medpace in the third quarter valued at $105,000. Finally, Hanlon Investment Management Inc. purchased a new position in shares of Medpace during the 3rd quarter valued at $787,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of research reports. Robert W. Baird boosted their price objective on Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a research note on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 price target on the stock. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and raised their price objective for the stock from $340.00 to $450.00 in a report on Tuesday. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and boosted their target price for the company from $282.00 to $452.00 in a report on Thursday, February 15th. Finally, StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $395.60.

Medpace Trading Up 8.2 %

Shares of NASDAQ:MEDP opened at $407.15 on Wednesday. The company has a 50 day moving average of $397.68 and a 200 day moving average of $323.14. The stock has a market cap of $12.61 billion, a P/E ratio of 45.85, a P/E/G ratio of 1.97 and a beta of 1.38. Medpace Holdings, Inc. has a 12 month low of $187.03 and a 12 month high of $419.42.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The firm had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. During the same period in the previous year, the business earned $2.27 EPS. The business’s revenue for the quarter was up 17.7% on a year-over-year basis. On average, equities analysts forecast that Medpace Holdings, Inc. will post 10.53 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the sale, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of Medpace stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the sale, the insider now owns 5,525,959 shares of the company’s stock, valued at $2,135,175,298.01. The disclosure for this sale can be found here. Insiders sold a total of 189,340 shares of company stock worth $76,651,647 over the last ninety days. 20.30% of the stock is owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.